Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.
作者： Giovanni Ferrara , Fabrizio Luppi , Surinder S. Birring , Stefania Cerri , Antonella Caminati
DOI: 10.1183/16000617.0076-2017
关键词: Evidence-based medicine 、 MEDLINE 、 Disease 、 In patient 、 Intensive care medicine 、 Psychological intervention 、 Quality of life 、 Medicine 、 Natural history 、 Idiopathic pulmonary fibrosis
摘要: Best supportive care (BSC) is generally defined as all the interventions and multiprofessional approach aimed to improve optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes might be complementary other directly targeting disease. BSC improves survival with different types cancer. Patients idiopathic pulmonary fibrosis (IPF) experience a vast range symptoms during natural history disease have beneficial effect interventions. This review highlights current evidence on QoL gaps for clinical assessment treatment IPF patients. Very few or symptom control are currently supported well-designed studies. Sound methodology paramount evaluating IPF, well use validated tools measure specific group
core.ac.uk
elsevier.com
sci-hub.se 参考文章(102)
Christine L. Vigeland, Andrew H. Hughes, Maureen R. Horton, Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respiratory Medicine. ,vol. 123, pp. 98- 104 ,(2017) , 10.1016/J.RMED.2016.12.016
Leona M Dowman, Christine F McDonald, Catherine J Hill, Annemarie L Lee, Kathryn Barker, Claire Boote, Ian Glaspole, Nicole S L Goh, Anne M Southcott, Angela T Burge, Rebecca Gillies, Alicia Martin, Anne E Holland, The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial Thorax. ,vol. 72, pp. 610- 619 ,(2017) , 10.1136/THORAXJNL-2016-208638
Leona M. Dowman, Christine F. McDonald, Steven Bozinovski, Ross Vlahos, Rebecca Gillies, Dodie Pouniotis, Catherine J. Hill, Nicole S.L. Goh, Anne E Holland, Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology. ,vol. 22, pp. 957- 964 ,(2017) , 10.1111/RESP.13002
Katrina Curtis, Nicholas S Hopkinson, Exercise training in interstitial lung disease: lumping or splitting? Thorax. ,vol. 72, pp. 589- 590 ,(2017) , 10.1136/THORAXJNL-2016-209929
Mark G Jones, Luca Richeldi, Harold R Collard, Idiopathic pulmonary fibrosis The Lancet. ,vol. 389, pp. 1941- 1952 ,(2017) , 10.1016/S0140-6736(17)30866-8
Michael Kreuter, Paolo Spagnolo, Wim Wuyts, Elisabetta Renzoni, Dirk Koschel, Francesco Bonella, Toby M Maher, Martin Kolb, Derek Weycker, Klaus-Uwe Kirchgässler, Ulrich Costabel, None, Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration. ,vol. 93, pp. 415- 423 ,(2017) , 10.1159/000468546
Michael Kreuter, Jeff Swigris, David Pittrow, Silke Geier, Jens Klotsche, Antje Prasse, Hubert Wirtz, Dirk Koschel, Stefan Andreas, Martin Claussen, Christian Grohé, Henrike Wilkens, Lars Hagmeyer, Dirk Skowasch, Joachim F Meyer, Joachim Kirschner, Sven Gläser, Felix J. F. Herth, Tobias Welte, Claus Neurohr, Martin Schwaiblmair, Matthias Held, Thomas Bahmer, Marion Frankenberger, Jürgen Behr, Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research. ,vol. 18, pp. 1- 10 ,(2017) , 10.1186/S12931-017-0621-Y
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J. Ryerson, Dominique Valeyre, Jan C. Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser, Wim A. Wuyts, Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine. ,vol. 197, pp. 356- 363 ,(2017) , 10.1164/RCCM.201706-1301OC
Kathleen Oare Lindell, Nonpharmacological Therapies for Interstitial Lung Disease Current Pulmonology Reports. ,vol. 7, pp. 126- 132 ,(2018) , 10.1007/S13665-018-0211-6
Zelin Lei, Xue Bai, Jianxiu Ma, Qin Yu, Kisspeptin‑13 inhibits bleomycin‑induced pulmonary fibrosis through GPR54 in mice Molecular Medicine Reports. ,vol. 20, pp. 1049- 1056 ,(2019) , 10.3892/MMR.2019.10341